Phibro Animal Health Corporation (PAHC) Receives News Sentiment Score of 0.18
Press coverage about Phibro Animal Health Corporation (NASDAQ:PAHC) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Phibro Animal Health Corporation earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.4112068370058 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Phibro Animal Health Corporation (PAHC) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Phibro Animal Health Corp. breached its 50 day moving average in a Bearish Manner : PAHC-US : October 31, 2017 (finance.yahoo.com)
- Phibro Animal Health Corporation (PAHC) Rating Increased to Buy at Zacks Investment Research (americanbankingnews.com)
- Phibro Animal Health Corporation (PAHC) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
Phibro Animal Health Corporation (NASDAQ PAHC) opened at $37.70 on Friday. Phibro Animal Health Corporation has a fifty-two week low of $24.85 and a fifty-two week high of $40.25. The firm has a market cap of $1,503.74, a PE ratio of 24.97, a PEG ratio of 4.41 and a beta of 1.35. The company has a current ratio of 3.14, a quick ratio of 1.75 and a debt-to-equity ratio of 2.03.
Phibro Animal Health Corporation (NASDAQ:PAHC) last posted its earnings results on Wednesday, August 30th. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $194.84 million during the quarter, compared to the consensus estimate of $192.47 million. Phibro Animal Health Corporation had a net margin of 8.45% and a return on equity of 47.88%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.32 earnings per share. sell-side analysts forecast that Phibro Animal Health Corporation will post 1.57 EPS for the current fiscal year.
Several equities analysts have recently weighed in on the stock. BidaskClub lowered shares of Phibro Animal Health Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 23rd. Bank of America Corporation reiterated an “underperform” rating and set a $33.00 price objective on shares of Phibro Animal Health Corporation in a report on Wednesday, August 23rd. Piper Jaffray Companies set a $35.00 price objective on shares of Phibro Animal Health Corporation and gave the company a “buy” rating in a report on Friday, July 21st. Credit Suisse Group upped their price objective on shares of Phibro Animal Health Corporation from $36.00 to $37.00 and gave the company an “outperform” rating in a report on Thursday, August 31st. Finally, Zacks Investment Research lowered shares of Phibro Animal Health Corporation from a “buy” rating to a “hold” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Phibro Animal Health Corporation has an average rating of “Hold” and a consensus target price of $34.60.
In other news, insider Dean J. Warras sold 10,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $35.70, for a total transaction of $357,000.00. Following the completion of the sale, the insider now directly owns 10,000 shares of the company’s stock, valued at $357,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel M. Bendheim sold 5,938 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $40.04, for a total transaction of $237,757.52. Following the sale, the vice president now directly owns 300 shares of the company’s stock, valued at $12,012. The disclosure for this sale can be found here. Over the last three months, insiders have sold 292,448 shares of company stock valued at $10,624,994. 51.88% of the stock is currently owned by insiders.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.